Regeneron Pharmaceuticals, Inc.

Matthew Sleeman

William C Olson

Andrew J Murphy

Jesper Gromada

Robert Babb

Amy Han

Viktoria Gusarova

Dimitris Skokos

Sokol Haxhinasto

Yu Huang

Drew Dudgeon

Bei Wang

Rosalynn Molden

Thomas Nittoli

Christos Kyratsous

Anna Zumsteg

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Therapeutic uses of anti-GITR antibodies

Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.

Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists

Anti-GITR antibodies and uses thereof

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

Anti-MSR1 antibodies and methods of use thereof

Growing community of inventors

White Plains, NY, United States of America

Matthew Sleeman